Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics 
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Dopaminergic-Related
Inhibitors |
|
Cat.No. |
Product Name / Activity |
| 3306 | 8-(3-Chlorostyryl)caffeine |
| MAO-B inhibitor. Also A2A antagonist | |
| 0767 | Bifemelane hydrochloride |
| MAO-A and MAO-B inhibitor | |
| 0455 | (S)-(-)-Carbidopa |
| Aromatic L-amino acid decarboxylase inhibitor | |
| 1095 | (R)-(-)-Deprenyl hydrochloride |
| MAO-B inhibitor | |
| 1132 | Harmane |
| MAO-A and MAO-B inhibitor | |
| 2460 | Lazabemide hydrochloride |
| Selective MAO-B inhibitor | |
| 0584 | L-(-)-α-Methyldopa |
| Aromatic L-amino acid decarboxylase inhibitor | |
| 4395 | Moclobemide |
| Reversible MAO-A inhibitor | |
| 0483 | OR-486 |
| Catechol-O-methyl transferase inhibitor | |
| 0730 | 4-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride |
| DA release inhibitor | |
| 0724 | Pirlindole mesylate |
| MAO-A inhibitor | |
| 4308 | Rasagiline mesylate |
| Selective, irreversible MAO-B inhibitor | |
| 0723 | Tetrindole mesylate |
| MAO-A inhibitor | |
Other |
|
Cat.No. |
Product Name / Activity |
| 2813 | D-Amphetamine sulfate |
| Induces dopamine, 5-HT and noradrenalin release | |
| 2875 | Homovanillic acid |
| Catecholamine metabolite | |
| 2547 | 6-Hydroxydopamine hydrobromide |
| Selective catecholaminergic neurotoxin | |
| 1929 | Melanocyte stimulating hormone release inhibiting factor |
| Increases brain dopamine levels. Also anti-opioid and inhibits α-MSH release | |
| 1811 | Modafinil |
| Psychostimulant | |
| 2599 | OSU 6162 hydrochloride |
| Dopamine stabilizer | |
| 3045 | Pemoline |
| CNS stimulant, indirect monoamine agonist | |
Quick Order
Find multiple products by catalog number
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.